Lu Min, a researcher at the Shanghai Institute of Hematology at Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine, recipient of the Overseas High level Youth Talent Program, leader of the National Key Research and Development Program Protein Key Special Project, recipient of the National Natural Science Foundation of China Key Project and Excellent Youth Project, recipient of the Royal Society Newton Advances Fellowship, and Shanghai Leading Talent.
Engaged in long-term research on the targeting of tumor suppressor protein p53. The main scientific discoveries include: 1) the discovery of a new mechanism for transcriptional regulation of wild-type p53 (Cancer Cell 2013); 2) Discovery of a novel RADAR nuclear localization signal (Cell 2014); 3) Propose a new strategy for regulating p53 transcription function (Nat Rev Mol Cell Biol 2016); 4) Obtained the first effective p53 mutant tumor suppressor function restorer ATO (Cancer Cell 2021); 5) Using its p53 restorer, it successfully targeted p53 mutants in the human body for the first time and achieved preliminary therapeutic effects (Sci Transl Med 2023); 6) In a head to head comparison of 10 evaluation systems, its p53 restorer was validated as the only internationally effective p53 restorer (Cancer Cell 2024). Its p53 restorer patent has entered major countries around the world such as China, the United States, the European Union, and Japan, and the right to use it in China has been granted to enterprises. Its p53 restorer has entered 5 clinical trials registered in ClnincalTrials, making it the most extensively researched p53 restorer in clinical trials worldwide. The research results have been recommended and introduced by international organizations or institutions such as TP53 Trust, Anti cancer Fund, REDO, etc., and have been rated as one of the top ten pharmaceutical events in China in 2020. The scientific discovery of the substantial acquisition of p53 restorers has the potential to open up the research field of tumor suppressor protein targeted therapy.